Lipoprotein(a) [Lp(a)]
Unlike LDL or triglycerides, lipoprotein(a) levels are over 80–90% determined by genetics — diet and lifestyle have minimal effect on it. It's the one lipid marker worth testing once in a lifetime, not periodically.
Number of studies
2
Safety
Requires caution
Time to effects
Not applicable — Lp(a) is a diagnostic test, not an intervention.
Who it's for
Table of contents
TL;DR
Unlike LDL or triglycerides, lipoprotein(a) levels are over 80–90% determined by genetics — diet and lifestyle have minimal effect on it. It's the one lipid marker worth testing once in a lifetime, not periodically.
- →Reveals a genetically determined component of cardiovascular risk that's independent of a standard lipid panel
- →A result established once remains valid for decades, without needing periodic repeat testing like LDL or triglycerides
- →An elevated result in one person is a signal to consider screening first-degree relatives
| Test type | A blood test assessing the genetically determined Lp(a) particle, independent of classic LDL |
|---|---|
| Level of evidence | Strong — the AHA and EAS recognize Lp(a) as a causal risk factor for atherosclerosis |
| Target group | Every adult, once in a lifetime; especially people with premature heart disease in the family |
| Key parameter | Lp(a) concentration — 70–90% genetically determined, essentially constant throughout life |
| Preparation | Doesn't require fasting — the result doesn't depend on your last meal |
| Status | A test recommended once in a lifetime, not for routine periodic repeat testing |
Understand
Overview
Lipoprotein(a), abbreviated Lp(a), is a particle structurally similar to LDL with an additional protein, apolipoprotein(a), attached to it — giving it distinct, partly LDL-independent atherogenic and prothrombotic properties. Unlike LDL cholesterol, triglycerides, or even ApoB, all of which can be meaningfully modified through diet, exercise, or weight loss, Lp(a) concentration is roughly 70–90% determined by genetic variation in the LPA gene and stays relatively constant in a given person throughout adult life.
This has direct practical consequences: the American Heart Association (AHA) and the European Atherosclerosis Society (EAS) recommend measuring Lp(a) at least once in every adult's lifetime, because unlike a standard lipid panel, it doesn't need to be repeated periodically — a result established once remains valid for decades. Roughly one in five people is estimated to have a clinically significant elevation of Lp(a), often without knowing it, since the test isn't part of a standard, routine lipid panel.
Who can genuinely benefit from this? Above all, people with premature cardiovascular disease in the family, especially when it isn't explained by a classic lipid profile, as well as people who had a heart attack or stroke despite normal LDL-C. Because Lp(a) levels are largely hereditary, an elevated result in one person is a reason to consider cascade screening in their first-degree relatives.
Mechanism of action
The Lp(a) particle forms when apolipoprotein(a) — a protein synthesized in the liver and structurally related to plasminogen, a protein of the fibrinolytic system — binds covalently to an LDL particle. This dual structural resemblance explains Lp(a)'s two-pronged mechanism of harm: the LDL-like portion penetrates the vessel wall and becomes oxidized, triggering an inflammatory cascade analogous to classic LDL-driven atherogenesis, while the apolipoprotein(a) portion, resembling plasminogen, can competitively block plasminogen binding sites, impairing the body's natural ability to dissolve clots (fibrinolysis) and favoring thrombosis.
The size of the apolipoprotein(a) molecule varies and is determined by the number of repeats of the so-called kringle IV type 2 domain in the LPA gene — fewer repeats (a smaller molecule) generally means higher circulating Lp(a), since smaller isoforms are secreted by the liver more efficiently. This genetic variability, almost entirely inherited rather than acquired over a lifetime, explains why Lp(a) stays stable in a given person regardless of diet, weight, or activity level — unlike LDL, HDL, or triglycerides, which respond strongly to environmental factors.
Apolipoprotein(a) binds to an LDL particle
Apo(a), structurally related to plasminogen, binds covalently to LDL, forming Lp(a).
Atherogenic effect of the LDL-like portion
The LDL-like fragment penetrates the artery wall and becomes oxidized, triggering inflammation as with classic LDL.
Prothrombotic effect of apo(a)
Apo(a)'s resemblance to plasminogen lets it competitively block fibrinolysis, favoring clot formation.
Evidence: strong — based on 2 studies in this database.
Benefits
Common myths
MythDiet and lifestyle changes will lower elevated Lp(a) the way they lower LDL.
FactBecause Lp(a) is 70–90% genetically determined, diet, exercise, and weight loss have minimal, clinically modest effect on it — unlike LDL or triglycerides.
MythSince Lp(a) is genetic and essentially unchangeable, testing it serves no practical purpose.
FactKnowing your Lp(a) level lets your doctor more accurately assess overall cardiovascular risk and manage the remaining, modifiable risk factors (LDL, blood pressure, smoking) more intensively if the result is elevated.
Check your profile
Not sure which supplements actually make sense for you?
Answer a few short questions about your lifestyle, diet, sleep, and goals. VitMode will build your profile and show supplements worth considering — with reasoning and evidence strength.
Recommendations take your answers and the strength of the scientific evidence into account. A supplement's popularity has no bearing on whether it gets recommended.
Practice
Frequently asked questions
Unlike a standard lipid panel, Lp(a) only needs to be measured once in a lifetime, since its level is largely genetically determined and stays relatively constant throughout adult life.
Diet and lifestyle changes have minimal effect on Lp(a), since it's 70–90% genetically determined — unlike LDL or triglycerides, which respond strongly to those factors.
Because Lp(a) levels are strongly hereditary, an elevated result in one person is usually a reason to consider screening first-degree relatives (parents, siblings, children).
What to combine with
Good combinations
Lipid Panel — Lp(a) adds an independent, genetically determined risk component to a standard lipid panel that LDL-C and HDL-C won't capture
Apolipoprotein B (ApoB) — Because the Lp(a) particle itself contains one ApoB copy, a high Lp(a) can partly raise ApoB too — worth interpreting them together
Safety
Side effects & contraindications
Possible side effects
Contraindications
No significant contraindications at typical doses.
Interactions
Unlike LDL and triglycerides, Lp(a) doesn't require fasting and doesn't change meaningfully with diet, exercise, or weight change
Pregnancy, acute inflammation, and kidney disease can temporarily raise the result independent of the genetically set baseline
Hormone therapy (estrogens) and some newer lipid-lowering drugs (PCSK9 inhibitors, niacin) can lower Lp(a), unlike most classic LDL-lowering medications
Is it worth taking?
Who it's for
- People with premature cardiovascular disease in the family, especially when it isn't explained by a classic lipid panel
- People who had a heart attack or stroke despite normal LDL-C, as well as first-degree relatives of someone with a confirmed elevated Lp(a)
Not for
- No significant contraindications at typical doses.
Evidence
Worth knowing
Roughly 70–90% of the variability in Lp(a) levels between people is directly explained by genotype at the LPA gene.
An estimated one in five people has a clinically significant elevation of Lp(a), often unknowingly, since it isn't part of a standard lipid panel.
Studies
Lipoprotein(a) is a genetically determined, causal, and prevalent risk factor for atherosclerotic cardiovascular disease, with 70% to over 90% of interindividual variability explained by genotype.
Reyes-Soffer G et al., Arteriosclerosis, Thrombosis, and Vascular Biology, 2022 (AHA Scientific Statement)
Lipoprotein(a): A Genetically Determined, Causal, and Prevalent Risk Factor for Atherosclerotic Cardiovascular Disease: A Scientific Statement From the American Heart Association
Strong evidenceReyes-Soffer G, Ginsberg HN, Berglund L, et al. · Arteriosclerosis, Thrombosis, and Vascular Biology · 2022
An official American Heart Association statement summarizing the evidence for Lp(a)'s causal role in atherosclerotic cardiovascular disease and its strong genetic basis.
View studyLipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European Atherosclerosis Society consensus statement
Strong evidenceKronenberg F, Mora S, Stroes ESG, et al. · European Heart Journal · 2022
A European Atherosclerosis Society consensus on Lp(a)'s role in cardiovascular disease and aortic stenosis, with guidance on testing and management of elevated results.
View studySources & bibliography
- Reyes-Soffer et al. 2022 — ATVB (AHA Scientific Statement)
- Kronenberg et al. 2022 — European Heart Journal (EAS Consensus Statement)
Citations are illustrative for this demo version and require full bibliographic verification by the editorial team before production publication.
Compare with similar entries
About the authors of this entry
Author
dr Katarzyna LewandowskaCardiologist
Katarzyna works as a cardiologist at a Warsaw teaching hospital and has spent years focused on cardiovascular prevention — trying, as she puts it, to convince people to change their habits before they end up on her ward, not after. She joined VitMode after a series of conversations with Anna at a lifestyle-medicine conference, where the two discovered they shared the same frustration: an internet full of contradictory claims about cholesterol, aspirin and heart supplements, with no clear signal of what's actually backed by research. She reviews content on cardiovascular health, lipid panels and pharmacological prevention, consistently distinguishing what helps a statistical population from what makes sense for a specific person. Off duty, she road-cycles — not for performance, but because, in her words, it's hard to write credibly about prevention without practicing it yourself.
20 publications on this site
Medical review
dr Anna KowalczykEditor-in-Chief, Molecular Biology
Anna studied molecular biology at the University of Warsaw, then spent eight years after her PhD in a lab researching the mechanisms of cellular aging and autophagy. She stumbled into science journalism almost by accident — frustrated by how easily her field's findings get oversimplified in the media, she started a blog explaining the biology of aging in plain language. That blog became the seed of VitMode. Today Anna oversees the entire editorial process, holding every piece to the same rigor her old lab demanded: primary sources, methodology checks, and honesty about the limits of the evidence. Outside work, she's a dedicated boulderer.
148 publications on this site
Related entries
4.6Lipid Panel
The lipid panel is one of the most important — and still one of the most frequently misread — preventive blood tests: 'total cholesterol' alone tells you less than the ratios between its fractions.
4.6Apolipoprotein B (ApoB)
While a standard lipid panel measures the amount of cholesterol carried in your blood, apolipoprotein B measures something different — the number of particles themselves that can actually penetrate the artery wall. That distinction can matter when a standard lipid panel looks fine but cardiovascular risk remains elevated.
4.6Metabolic Syndrome
A cluster of five risk factors — from abdominal obesity to elevated triglycerides — that multiplies the risk of type 2 diabetes and cardiovascular disease, but is largely modifiable through lifestyle change.
4.5Homocysteine
Homocysteine is an intermediate amino acid of methionine metabolism, linked for decades to cardiovascular and neurological risk — though how much lowering it actually reduces that risk remains a point of controversy in the literature.
4.5TRT and Cholesterol — How Does Testosterone Affect Your Lipid Profile?
Testosterone therapy usually lowers total cholesterol and LDL slightly, but it often lowers HDL too — which historically raised concern. We explain why these changes rarely translate into a real worsening of cardiovascular risk, and how to read a lipid panel in the context of TRT.
4.4Statins
The best-researched class of LDL-cholesterol-lowering drugs, with one of the largest evidence bases in all of cardiology — yet still surrounded by numerous, largely unfounded fears.
4.3Shiitake
A culinary-functional mushroom rich in lentinan and beta-glucans, studied clinically for immune modulation and lipid profile — one of the best-researched functional mushrooms on the market.
Related articles
PoradnikiMuscle Pain from Statins: Drug Effect or Nocebo?
Millions of patients stop taking statins because of muscle pain that, according to the first trial ever designed to settle the question, has nothing to do with the drug's pharmacology in 90% of cases. In the SAMSON experiment, participants reported nearly identical pain severity while taking the statin and while taking a placebo. That doesn't mean the pain is 'imaginary' — it means the pill itself, not its active ingredient, is usually not the source.
August 23, 2026
PoradnikiGarlic and LDL Cholesterol: Does It Really Lower It?
"Garlic lowers cholesterol" is one of the oldest folk health tips — and, rare for this category, partly confirmed by meta-analyses of clinical trials. But the devil is in the details: the effect is real (an LDL drop of about 9 mg/dL), yet it applies only to people with already elevated cholesterol, requires supplementation lasting more than 2 months, and has nothing to do with occasionally tossing a clove of garlic into dinner.
August 23, 2026
PoradnikiEggs and Blood Cholesterol: Does an Egg-Rich Diet Harm Your Heart?
For decades, eggs served as the poster child for a food to "avoid" if you cared about your heart — because of the high cholesterol content in the yolk. The newest, massive analysis combining three prospective US cohorts (215,618 people, followed for up to 32 years) and an updated meta-analysis spanning 1.72 million participants worldwide paints a far calmer picture: eating up to one egg a day shows no significant association with elevated cardiovascular risk. In Asian cohorts, researchers even observed a mild protective effect. This is one of those cases where the scale and quality of newer data shifts conclusions from decades past — not because the old studies were poorly done, but because newer analyses have the statistical power to catch nuances smaller samples couldn't see. In this article, we look at exactly what the numbers show, where certainty ends, and where nuance begins.
August 24, 2026
PoradnikiStatins and Type 2 Diabetes Risk: Do Cholesterol Drugs Raise Your Risk?
Statins are among the most widely prescribed drugs on earth, and their benefit in preventing heart attacks and strokes is one of the best-documented facts in all of cardiology. Less often discussed is another well-confirmed effect: statins genuinely increase the risk of newly diagnosed type 2 diabetes — not a fringe finding from a single study, but a result confirmed independently in the randomized JUPITER trial and in a meta-analysis of 13 trials covering more than 91,000 participants. The key, often-missed nuance is different from what the headline suggests: the increased risk falls almost entirely on people who already had diabetes risk factors, and the cardiovascular benefit of statins — even in that same group — is several times larger than the risk of causing one extra case of diabetes. This article explains why both facts are true at once, and why the authors of both studies, despite confirming the effect, unambiguously recommend continuing statin therapy.
August 25, 2026
Comments (2)
- KW
Kasia W. 2 weeks ago
Very clearly explained, especially the interactions section — I hadn't seen it laid out this well anywhere else.
- MT
Marek T. a month ago
Are you planning to update this with the newest study from this year? I saw an interesting meta-analysis.